Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established as effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as monotherapy or in combination with oral glucose-lowering drugs ± insulin. The six subcutaneous GLP-1RA formulations (i.e. twice-daily...

Descripción completa

Detalles Bibliográficos
Autor principal: Lyseng-Williamson, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Adis Disease Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746674/
https://www.ncbi.nlm.nih.gov/pubmed/31317516
http://dx.doi.org/10.1007/s40261-019-00826-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746674/
https://www.ncbi.nlm.nih.gov/pubmed/31317516
http://dx.doi.org/10.1007/s40261-019-00826-0

Ejemplares similares